Fate Therapeutics, Inc.

FATE · NasdaqGM

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders1.1%

Institutions69.0%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$6.65M	$13.63M	$96.30M	$55.85M	$31.43M	$10.68M	$4.74M	–	–	$2.43M
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$147.70M	-$210.28M	-$308.39M	-$216.99M	-$128.09M	-$100.73M	-$67.09M	-$42.13M	-$31.96M	-$27.78M
Operating income as a percentage of revenue.	-2222.4%	-1542.6%	-320.2%	-388.6%	-407.5%	-943.1%	-1415.4%	–	–	-1142.8%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$136.31M	-$186.26M	-$281.72M	-$212.15M	-$173.39M	-$98.15M	-$66.60M	-$42.95M	-$33.46M	-$29.99M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-1.15	$-1.64	$-2.00	$-2.24	$-2.10	$-1.00	$-1.00	$-1.00	$-1.00	$-1.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-1.15	$-1.64	$-2.00	–	–	–	–	–	–	–

Balance Sheet

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$46.63M	$36.06M	$61.33M	$133.58M	$167.35M	$99.81M	$190.51M	$88.95M	$88.61M	$64.81M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$318.94M	$440.69M	$705.56M	$921.46M	$622.46M	$302.27M	$213.03M	$105.29M	$95.05M	$67.96M
All of the company's interest-bearing borrowings, short and long term combined.	–	–	–	–	–	–	$14.88M	$14.81M	$10.69M	$18.24M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$207.18M	$318.73M	$483.94M	$678.84M	$384.44M	$244.76M	$160.47M	$77.19M	$73.15M	-$142.38M

Cash Flow Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$106.08M	-$122.87M	-$248.21M	-$162.87M	-$39.23M	-$83.17M	-$38.65M	-$36.91M	-$29.82M	-$18.40M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$5.95M	$730000	$35.57M	$50.70M	$4.93M	$7.39M	$2.30M	$1.73M	$457000	$1.50M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$112.04M	-$123.60M	-$283.77M	-$213.57M	-$44.16M	-$90.57M	-$40.95M	-$38.63M	-$30.28M	-$19.89M

	You	Peer avg
Revenue Growth	+9.2%	-7.7%
ROE	-60.8%	-51.2%

Fate Therapeutics, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison